IGC Pharma, Inc.
IGC
$0.32
$0.000.72%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 191.00K | 328.00K | 330.00K | 257.00K | 412.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 191.00K | 328.00K | 330.00K | 257.00K | 412.00K |
| Cost of Revenue | 92.00K | 174.00K | 176.00K | 153.00K | 214.00K |
| Gross Profit | 99.00K | 154.00K | 154.00K | 104.00K | 198.00K |
| SG&A Expenses | 1.41M | 1.21M | 619.00K | 1.13M | 1.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.09M | 2.23M | 1.79M | 2.14M | 2.17M |
| Operating Income | -2.90M | -1.90M | -1.46M | -1.88M | -1.76M |
| Income Before Tax | -1.82M | -1.60M | -1.20M | -1.83M | -1.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.82M | -1.60M | -1.20M | -1.83M | -1.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.82M | -1.60M | -1.20M | -1.83M | -1.72M |
| EBIT | -2.90M | -1.90M | -1.46M | -1.88M | -1.76M |
| EBITDA | -2.78M | -1.76M | -1.31M | -1.72M | -1.62M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 90.46M | 83.03M | 79.59M | 77.63M | 76.01M |
| Average Diluted Shares Outstanding | 90.46M | 83.03M | 79.59M | 77.63M | 76.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |